|University of Oxford, D.Phil.||1999|
|Penn State University, BS||1996|
Dr. Bruce Booth (Ph.D.) is the Board Director of Zafgen.
Dr. Booth joined Atlas Venture in 2005, and currently serves as partner in the life sciences group, focusing on new and emerging companies developing novel biotech or pharmaceutical products, therapeutic platforms and innovative biomedical technologies.
Previously, Dr. Booth was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm’s private equity activities, ranging from early stage venture capital through late stage buyouts.
Prior to Caxton, he was an associate principal at McKinsey & Company, a global strategic management consulting firm, where he advised clients on R&D productivity, corporate strategy and business development issues across the biopharmaceutical sector.
Dr. Booth currently serves as a trustee of the New York Academy of Medicine, and is a term member of the council on foreign relations.
As a British Marshall Scholar, Dr. Booth earned his Ph.D. in molecular immunology from the Oxford University’s Nuffield department of medicine.
He received his B.S. in biochemistry from the Pennsylvania State University.